Cardiac Transplantation in Patients With Hypertrophic Cardiomyopathy

被引:47
|
作者
Kato, Tomoko S. [1 ]
Takayama, Hiroo [2 ]
Yoshizawa, Saeko [3 ]
Marboe, Charles [3 ]
Schulze, P. Christian [1 ]
Farr, Maryjane [1 ]
Naka, Yoshifumi [2 ]
Mancini, Donna [1 ]
Maurer, Mathew S. [1 ]
机构
[1] Columbia Univ, Dept Med, Div Cardiol, Med Ctr, New York, NY 10027 USA
[2] Columbia Univ, Dept Surg, Div Cardiothorac Surg, Med Ctr, New York, NY USA
[3] Columbia Univ, Dept Pathol, Med Ctr, New York, NY USA
关键词
MUSCLE CELL DISORGANIZATION; LEFT-VENTRICULAR HYPERTROPHY; HEART-TRANSPLANTATION; CLINICAL-SIGNIFICANCE; ATHLETES HEART; SURVIVAL; PREVALENCE; INFECTION; DIAGNOSIS; FEATURES;
D O I
10.1016/j.amjcard.2012.04.030
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiac transplantation is a treatment option for patients with hypertrophic cardiomyopathy (HC) who developed refractory heart failure and/or intractable arrhythmia. However, the pretransplant characteristics and post-transplant prognosis for patients with nondilated idiopathic HC has not yet fully elucidated. Therefore, we retrospectively reviewed 813 consecutive transplant recipients undergoing cardiac transplantation at Columbia University Medical Center from 1999 to 2010 and compared the clinical course of 41 patients with idiopathic HC with that of 373 patients with ischemic heart disease and 398 patients with other heart disease. The patients with HC were younger than those with ischemic heart disease (47.8 +/- 14.0 vs 57.1 +/- 9.4 years; p <0.0001). The proportion of patients undergoing ventricular assist devise surgery for bridge-to-transplant was lower in patients with HC than in those with ischemic heart disease or other heart disease (14.6% vs 31.1% vs 35.7%, all p <0.01). The post-transplant survival of those with HC was better than that for those with ischemic heart disease (90.1% vs 85.8% and 83.9% vs 67.1% at 1 and 5 years, respectively; p = 0.0359), although it was not significantly different from those with other heart disease. Proportional hazards analysis revealed that the subjects with HC had reduced post-transplant mortality (hazard ratio 0.4760, 95% confidential interval 0.1889 to 0.9762; p = 0.042) on univariate, but not multivariate, analysis. Most patients with HC had nondilated left ventricles (left ventricular end-diastolic dimension <= 55 mm; n = 27), and post-transplant survival did not differ from that for those with dilated left ventricles (left ventricular end-diastolic dimension >55 mm; n = 14). In conclusion, the post-transplant survival of those with HC did not differ from those of the subjects who underwent transplant for other non-HC indications. (C) 2012 Elsevier Inc. All rights reserved. (Am J Cardiol 2012;110:568-574)
引用
收藏
页码:568 / 574
页数:7
相关论文
共 50 条
  • [41] Hypertrophic Cardiomyopathy
    Subasic, Kim
    NURSING CLINICS OF NORTH AMERICA, 2013, 48 (04) : 571 - +
  • [42] Evaluation of Apical Subtype of Hypertrophic Cardiomyopathy Using Cardiac Magnetic Resonance Imaging With Gadolinium Enhancement
    Kebed, Kalie Y.
    Al Adham, Raed I.
    Bishu, Kalkidan
    Askew, J. Wells
    Klarich, Kyle W.
    Araoz, Philip A.
    Foley, Thomas A.
    Glockner, James F.
    Nishimura, Rick A.
    Anavekar, Nandan S.
    AMERICAN JOURNAL OF CARDIOLOGY, 2014, 114 (05) : 777 - 782
  • [43] Incremental benefit of late gadolinium cardiac magnetic resonance imaging for risk stratification in patients with hypertrophic cardiomyopathy
    Doesch, Christina
    Tulumen, Erol
    Akin, Ibrahim
    Rudic, Boris
    Kuschyk, Juergen
    El-Battrawy, Ibrahim
    Becher, Tobias
    Budjan, Johannes
    Smakic, Arman
    Schoenberg, Stefan O.
    Borggrefe, Martin
    Papavassiliu, Theano
    SCIENTIFIC REPORTS, 2017, 7
  • [44] Novel cardiac myosin inhibitor for hypertrophic cardiomyopathy
    Szczesna-Cordary, Danuta
    JOURNAL OF GENERAL PHYSIOLOGY, 2024, 156 (10)
  • [45] The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy
    Klopotowski, Mariusz
    Kukula, Krzysztof
    Malek, Lukasz A.
    Spiewak, Mateusz
    Polanska-Skrzypczyk, Magdalena
    Jamiolkowski, Jacek
    Dabrowski, Maciej
    Baranowski, Rafal
    Klisiewicz, Anna
    Kusmierczyk, Mariusz
    Jasinska, Anna
    Jarmus, Ewelina
    Kruk, Mariusz
    Ruzyllo, Witold
    Witkowski, Adam
    Chojnowska, Lidia
    JOURNAL OF CARDIOLOGY, 2016, 68 (1-2) : 49 - 56
  • [46] Prevention of sudden cardiac death in hypertrophic cardiomyopathy
    O'Mahony, Constantinos
    Elliott, Perry M.
    HEART, 2014, 100 (03) : 254 - 260
  • [47] Cardiac Magnetic Resonance Imaging and Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy
    McKenna, William J.
    Nagueh, Sherif F.
    CIRCULATION, 2014, 130 (06) : 455 - 457
  • [48] Effect of type 2 diabetes on cardiac arrhythmias in patients with obstructive hypertrophic cardiomyopathy
    Wang, Shengwei
    Zhang, Ke
    He, Meng
    Guo, Hongchang
    Cui, Hao
    Wang, Shuiyun
    Lai, Yongqiang
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2024, 18 (03)
  • [49] Perioperative outcomes of patients with hypertrophic cardiomyopathy undergoing non-cardiac surgery
    Dhillon, Ashwat
    Khanna, Ashish
    Randhawa, Mandeep Singh
    Cywinski, Jacek
    Saager, Leif
    Thamilarasan, Maran
    Lever, Harry M.
    Desai, Milind Y.
    HEART, 2016, 102 (20) : 1627 - 1632
  • [50] Effect of Renal Dysfunction on Risk of Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy
    Higuchi, Satoshi
    Minami, Yuichiro
    Shoda, Morio
    Shirotani, Shota
    Kanai, Miwa
    Kataoka, Shohei
    Yazaki, Kyoichiro
    Saito, Chihiro
    Haruki, Shintaro
    Yagishita, Daigo
    Ejima, Koichiro
    Hagiwara, Nobuhisa
    AMERICAN JOURNAL OF CARDIOLOGY, 2021, 144 : 131 - 136